75 related articles for article (PubMed ID: 38429886)
1. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
Waters R; Sewastjanow-Silva M; Yamashita K; Abdelhakeem A; Iwata KK; Moran D; Elsouda D; Guerrero A; Pizzi M; Vicentini ER; Shanbhag N; Ta A; Chatterjee D; Ajani JA
JCO Precis Oncol; 2024 May; 8():e2300543. PubMed ID: 38781542
[TBL] [Abstract][Full Text] [Related]
2. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Ajani J
Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
[TBL] [Abstract][Full Text] [Related]
3. Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada.
Snow S; Gabrielson D; Lim H; Tehfe M; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(5):2552-2565. PubMed ID: 38785472
[TBL] [Abstract][Full Text] [Related]
4. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.
Myer NM; Shitara K; Chung HC; Lordick F; Kelly RJ; Szabo Z; Cao ZA; Leong S; Ilson DH; Weichert W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2023-2043. PubMed ID: 35551464
[TBL] [Abstract][Full Text] [Related]
5. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
[TBL] [Abstract][Full Text] [Related]
6. The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review.
AlMazmomy AM; Al-Hayani MM; Alomari M; Bazi AG
Cureus; 2019 Dec; 11(12):e6295. PubMed ID: 31938588
[TBL] [Abstract][Full Text] [Related]
7. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.
Baykara M; Benekli M; Ekinci O; Irkkan SC; Karaca H; Demirci U; Akinci MB; Unal OU; Dane F; Turkoz FP; Balakan O; Eser EP; Ozturk SC; Ozkan M; Oksuzoglu B; Sevinc A; Demir N; Harputluoglu H; Yalcin B; Coskun U; Uner A; Ozet A; Buyukberber S;
J Gastrointest Surg; 2015 Sep; 19(9):1565-71. PubMed ID: 26179664
[TBL] [Abstract][Full Text] [Related]
10. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas.
Pellino A; Brignola S; Riello E; Niero M; Murgioni S; Guido M; Nappo F; Businello G; Sbaraglia M; Bergamo F; Spolverato G; Pucciarelli S; Merigliano S; Pilati P; Cavallin F; Realdon S; Farinati F; Dei Tos AP; Zagonel V; Lonardi S; Loupakis F; Fassan M
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834447
[TBL] [Abstract][Full Text] [Related]
11. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
[TBL] [Abstract][Full Text] [Related]
13. The Genomic Landscape of Urothelial Carcinoma with High and Low
Hadadi A; Krause HB; Elliott A; Brown JT; Nazha B; Harik LR; Carthon BC; Miron B; Nabhan C; Barata PC; Saleh M; Yang Y; McKay RR; Bilen MA
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136267
[TBL] [Abstract][Full Text] [Related]
14. HER2-low expression in patients with advanced or metastatic solid tumors.
Uzunparmak B; Haymaker C; Raso G; Masciari S; Wang L; Lin H; Gorur A; Kirby B; Cimo AM; Kennon A; Ding Q; Urschel G; Yuan Y; Feng G; Rizvi Y; Hussain A; Zhu C; Kim P; Abbadessa G; Subbiah V; Yap TA; Rodon J; Piha-Paul SA; Meric-Bernstam F; Dumbrava EE
Ann Oncol; 2023 Nov; 34(11):1035-1046. PubMed ID: 37619847
[TBL] [Abstract][Full Text] [Related]
15. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]